An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains
Although HIV subtype B predominates in North America and Western Europe, most HIV infections worldwide are non-subtype B. Globally effective AIDS vaccines need to elicit broad immunity against multiple HIV strains. In this study, 10 chimpanzees were intranasally primed sequentially with adenovirus t...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2006-11, Vol.43 (3), p.270-277 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 277 |
|---|---|
| container_issue | 3 |
| container_start_page | 270 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 43 |
| creator | Gómez-Román, V. Raúl Florese, Ruth H Peng, Bo Montefiori, David C Kalyanaraman, Vaniambadi S Venzon, David Srivastava, Indresh Barnett, Susan W Robert-Guroff, Marjorie |
| description | Although HIV subtype B predominates in North America and Western Europe, most HIV infections worldwide are non-subtype B. Globally effective AIDS vaccines need to elicit broad immunity against multiple HIV strains. In this study, 10 chimpanzees were intranasally primed sequentially with adenovirus type 5 (Ad5)- and Ad7-HIVMNenv/rev recombinants and boosted twice intramuscularly with heterologous oligomeric HIVSF162 gp140ΔV2 protein in MF59 adjuvant. Sera were evaluated for binding, neutralizing, and antibody-dependent cellular cytotoxicity (ADCC) against HIV clades A, B, C, and CRF01_AE. The vaccine regimen elicited high-titered HIV subtype A, B, C and CRF01_AE gp120-binding antibodies. Sera from 7 of 10 vaccinated chimpanzees cross-neutralized the heterologous South African subtype C primary HIVTV-1 isolate. Significant cross-clade neutralization against other subtype A, C and E isolates was not observed. Sera from all animals mediated ADCC of cells coated with gp120 from HIV subtypes A and B. Nine of 10 animals also exhibited ADCC activity against HIV subtype C and CRF01_AE gp120-coated targets. This subtype B Ad-HIV recombinant prime/envelope protein boost regimen is a promising approach for eliciting broad ADCC activity against diverse HIV clades. Incorporating additional non-subtype B envelope genes and protein boosts in a multivalent strategy may be required to elicit broader neutralizing antibodies against non-subtype B HIV strains. |
| doi_str_mv | 10.1097/01.qai.0000230318.40170.60 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69024970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69024970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4503-65cedfdf1b8c7a03680b8385b02f3c41ce51099b8181ecb61005e9a0d103f6c63</originalsourceid><addsrcrecordid>eNqFkd1u1DAQhSMEoqXwCsiqBHfZjmPHcbjbXQqtVH7ET28tx5m0Lqm9tR3KPhMvibe7aCVu8I0tz-c5x3OK4pjCjELbnACd3Wk7g7wqBozKGQfawEzAo-KQtpyXjZT8cT7XVV1yyuqD4lmMNwBUcN4-LQ6oaDnIWh4Wv-eOzHt0_qcNUywXOmJPzs4vydepS-sVkgX5HOwtniy8j4lcamOsQ_IFr_KlI6ejNTZFMnfJdr63GMkH7K1O1l2RRfC6_1tal29xhS5LJbLEcZxGHchynXzyvzY91mR-pa3LGh-9K_fqD15S2JSeF08GPUZ8sduPiu_vTr8tz8qLT-_Pl_OL0vAaWClqg_3QD7STptHAhIROMll3UA3McGqwzmNsO0klRdMJClBjq6GnwAZhBDsqXm_7roK_mzAmdWujyZ61Qz9FJVqoeNvAf8GchcxNeQaP_wFv_BRc_oSqGBOcNk2ToTdbyAQfY8BBrfLkdVgrCmoTvAKqcvBqH7x6CF6JjZWXO4Wpu8V-_3SXdAZe7QAdjR6HoJ2xcc_JSvJa1pnjW-7ejwlD_DFO9xjUNeoxXWdpWgnGeFkBCEqBQrlxw9gfYMzHJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>233641777</pqid></control><display><type>article</type><title>An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Ovid Autoload</source><source>Free E- Journals</source><creator>Gómez-Román, V. Raúl ; Florese, Ruth H ; Peng, Bo ; Montefiori, David C ; Kalyanaraman, Vaniambadi S ; Venzon, David ; Srivastava, Indresh ; Barnett, Susan W ; Robert-Guroff, Marjorie</creator><creatorcontrib>Gómez-Román, V. Raúl ; Florese, Ruth H ; Peng, Bo ; Montefiori, David C ; Kalyanaraman, Vaniambadi S ; Venzon, David ; Srivastava, Indresh ; Barnett, Susan W ; Robert-Guroff, Marjorie</creatorcontrib><description>Although HIV subtype B predominates in North America and Western Europe, most HIV infections worldwide are non-subtype B. Globally effective AIDS vaccines need to elicit broad immunity against multiple HIV strains. In this study, 10 chimpanzees were intranasally primed sequentially with adenovirus type 5 (Ad5)- and Ad7-HIVMNenv/rev recombinants and boosted twice intramuscularly with heterologous oligomeric HIVSF162 gp140ΔV2 protein in MF59 adjuvant. Sera were evaluated for binding, neutralizing, and antibody-dependent cellular cytotoxicity (ADCC) against HIV clades A, B, C, and CRF01_AE. The vaccine regimen elicited high-titered HIV subtype A, B, C and CRF01_AE gp120-binding antibodies. Sera from 7 of 10 vaccinated chimpanzees cross-neutralized the heterologous South African subtype C primary HIVTV-1 isolate. Significant cross-clade neutralization against other subtype A, C and E isolates was not observed. Sera from all animals mediated ADCC of cells coated with gp120 from HIV subtypes A and B. Nine of 10 animals also exhibited ADCC activity against HIV subtype C and CRF01_AE gp120-coated targets. This subtype B Ad-HIV recombinant prime/envelope protein boost regimen is a promising approach for eliciting broad ADCC activity against diverse HIV clades. Incorporating additional non-subtype B envelope genes and protein boosts in a multivalent strategy may be required to elicit broader neutralizing antibodies against non-subtype B HIV strains.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/01.qai.0000230318.40170.60</identifier><identifier>PMID: 16940858</identifier><identifier>CODEN: JDSRET</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adenoviridae - genetics ; Adenovirus ; Adenoviruses ; AIDS Vaccines - administration & dosage ; AIDS Vaccines - immunology ; AIDS/HIV ; Animals ; Biological and medical sciences ; Cross Reactions ; Drug Evaluation, Preclinical ; Fundamental and applied biological sciences. Psychology ; Genetic Vectors - immunology ; HIV ; HIV Antibodies - blood ; HIV Antibodies - immunology ; HIV Envelope Protein gp120 - immunology ; HIV Infections - immunology ; HIV Infections - prevention & control ; HIV-1 - classification ; HIV-1 - genetics ; HIV-1 - immunology ; Human immunodeficiency virus ; Human viral diseases ; Immune system ; Immunization, Secondary ; Infectious diseases ; Medical sciences ; Microbiology ; Miscellaneous ; Neutralization Tests ; Pan troglodytes ; Proteins ; Recombinant Proteins - immunology ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Synthetic - immunology ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Vaccines - administration & dosage ; Virology</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2006-11, Vol.43 (3), p.270-277</ispartof><rights>2006 Lippincott Williams & Wilkins, Inc.</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Lippincott Williams & Wilkins Nov 1, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4503-65cedfdf1b8c7a03680b8385b02f3c41ce51099b8181ecb61005e9a0d103f6c63</citedby><cites>FETCH-LOGICAL-c4503-65cedfdf1b8c7a03680b8385b02f3c41ce51099b8181ecb61005e9a0d103f6c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00126334-200611010-00003$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,777,781,4595,27905,27906,65212</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18284585$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16940858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Román, V. Raúl</creatorcontrib><creatorcontrib>Florese, Ruth H</creatorcontrib><creatorcontrib>Peng, Bo</creatorcontrib><creatorcontrib>Montefiori, David C</creatorcontrib><creatorcontrib>Kalyanaraman, Vaniambadi S</creatorcontrib><creatorcontrib>Venzon, David</creatorcontrib><creatorcontrib>Srivastava, Indresh</creatorcontrib><creatorcontrib>Barnett, Susan W</creatorcontrib><creatorcontrib>Robert-Guroff, Marjorie</creatorcontrib><title>An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>Although HIV subtype B predominates in North America and Western Europe, most HIV infections worldwide are non-subtype B. Globally effective AIDS vaccines need to elicit broad immunity against multiple HIV strains. In this study, 10 chimpanzees were intranasally primed sequentially with adenovirus type 5 (Ad5)- and Ad7-HIVMNenv/rev recombinants and boosted twice intramuscularly with heterologous oligomeric HIVSF162 gp140ΔV2 protein in MF59 adjuvant. Sera were evaluated for binding, neutralizing, and antibody-dependent cellular cytotoxicity (ADCC) against HIV clades A, B, C, and CRF01_AE. The vaccine regimen elicited high-titered HIV subtype A, B, C and CRF01_AE gp120-binding antibodies. Sera from 7 of 10 vaccinated chimpanzees cross-neutralized the heterologous South African subtype C primary HIVTV-1 isolate. Significant cross-clade neutralization against other subtype A, C and E isolates was not observed. Sera from all animals mediated ADCC of cells coated with gp120 from HIV subtypes A and B. Nine of 10 animals also exhibited ADCC activity against HIV subtype C and CRF01_AE gp120-coated targets. This subtype B Ad-HIV recombinant prime/envelope protein boost regimen is a promising approach for eliciting broad ADCC activity against diverse HIV clades. Incorporating additional non-subtype B envelope genes and protein boosts in a multivalent strategy may be required to elicit broader neutralizing antibodies against non-subtype B HIV strains.</description><subject>Adenoviridae - genetics</subject><subject>Adenovirus</subject><subject>Adenoviruses</subject><subject>AIDS Vaccines - administration & dosage</subject><subject>AIDS Vaccines - immunology</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cross Reactions</subject><subject>Drug Evaluation, Preclinical</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic Vectors - immunology</subject><subject>HIV</subject><subject>HIV Antibodies - blood</subject><subject>HIV Antibodies - immunology</subject><subject>HIV Envelope Protein gp120 - immunology</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - prevention & control</subject><subject>HIV-1 - classification</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Immune system</subject><subject>Immunization, Secondary</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Neutralization Tests</subject><subject>Pan troglodytes</subject><subject>Proteins</subject><subject>Recombinant Proteins - immunology</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Virology</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd1u1DAQhSMEoqXwCsiqBHfZjmPHcbjbXQqtVH7ET28tx5m0Lqm9tR3KPhMvibe7aCVu8I0tz-c5x3OK4pjCjELbnACd3Wk7g7wqBozKGQfawEzAo-KQtpyXjZT8cT7XVV1yyuqD4lmMNwBUcN4-LQ6oaDnIWh4Wv-eOzHt0_qcNUywXOmJPzs4vydepS-sVkgX5HOwtniy8j4lcamOsQ_IFr_KlI6ejNTZFMnfJdr63GMkH7K1O1l2RRfC6_1tal29xhS5LJbLEcZxGHchynXzyvzY91mR-pa3LGh-9K_fqD15S2JSeF08GPUZ8sduPiu_vTr8tz8qLT-_Pl_OL0vAaWClqg_3QD7STptHAhIROMll3UA3McGqwzmNsO0klRdMJClBjq6GnwAZhBDsqXm_7roK_mzAmdWujyZ61Qz9FJVqoeNvAf8GchcxNeQaP_wFv_BRc_oSqGBOcNk2ToTdbyAQfY8BBrfLkdVgrCmoTvAKqcvBqH7x6CF6JjZWXO4Wpu8V-_3SXdAZe7QAdjR6HoJ2xcc_JSvJa1pnjW-7ejwlD_DFO9xjUNeoxXWdpWgnGeFkBCEqBQrlxw9gfYMzHJA</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Gómez-Román, V. Raúl</creator><creator>Florese, Ruth H</creator><creator>Peng, Bo</creator><creator>Montefiori, David C</creator><creator>Kalyanaraman, Vaniambadi S</creator><creator>Venzon, David</creator><creator>Srivastava, Indresh</creator><creator>Barnett, Susan W</creator><creator>Robert-Guroff, Marjorie</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains</title><author>Gómez-Román, V. Raúl ; Florese, Ruth H ; Peng, Bo ; Montefiori, David C ; Kalyanaraman, Vaniambadi S ; Venzon, David ; Srivastava, Indresh ; Barnett, Susan W ; Robert-Guroff, Marjorie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4503-65cedfdf1b8c7a03680b8385b02f3c41ce51099b8181ecb61005e9a0d103f6c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenoviridae - genetics</topic><topic>Adenovirus</topic><topic>Adenoviruses</topic><topic>AIDS Vaccines - administration & dosage</topic><topic>AIDS Vaccines - immunology</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cross Reactions</topic><topic>Drug Evaluation, Preclinical</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic Vectors - immunology</topic><topic>HIV</topic><topic>HIV Antibodies - blood</topic><topic>HIV Antibodies - immunology</topic><topic>HIV Envelope Protein gp120 - immunology</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - prevention & control</topic><topic>HIV-1 - classification</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Immune system</topic><topic>Immunization, Secondary</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Neutralization Tests</topic><topic>Pan troglodytes</topic><topic>Proteins</topic><topic>Recombinant Proteins - immunology</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Román, V. Raúl</creatorcontrib><creatorcontrib>Florese, Ruth H</creatorcontrib><creatorcontrib>Peng, Bo</creatorcontrib><creatorcontrib>Montefiori, David C</creatorcontrib><creatorcontrib>Kalyanaraman, Vaniambadi S</creatorcontrib><creatorcontrib>Venzon, David</creatorcontrib><creatorcontrib>Srivastava, Indresh</creatorcontrib><creatorcontrib>Barnett, Susan W</creatorcontrib><creatorcontrib>Robert-Guroff, Marjorie</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Román, V. Raúl</au><au>Florese, Ruth H</au><au>Peng, Bo</au><au>Montefiori, David C</au><au>Kalyanaraman, Vaniambadi S</au><au>Venzon, David</au><au>Srivastava, Indresh</au><au>Barnett, Susan W</au><au>Robert-Guroff, Marjorie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>43</volume><issue>3</issue><spage>270</spage><epage>277</epage><pages>270-277</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><coden>JDSRET</coden><abstract>Although HIV subtype B predominates in North America and Western Europe, most HIV infections worldwide are non-subtype B. Globally effective AIDS vaccines need to elicit broad immunity against multiple HIV strains. In this study, 10 chimpanzees were intranasally primed sequentially with adenovirus type 5 (Ad5)- and Ad7-HIVMNenv/rev recombinants and boosted twice intramuscularly with heterologous oligomeric HIVSF162 gp140ΔV2 protein in MF59 adjuvant. Sera were evaluated for binding, neutralizing, and antibody-dependent cellular cytotoxicity (ADCC) against HIV clades A, B, C, and CRF01_AE. The vaccine regimen elicited high-titered HIV subtype A, B, C and CRF01_AE gp120-binding antibodies. Sera from 7 of 10 vaccinated chimpanzees cross-neutralized the heterologous South African subtype C primary HIVTV-1 isolate. Significant cross-clade neutralization against other subtype A, C and E isolates was not observed. Sera from all animals mediated ADCC of cells coated with gp120 from HIV subtypes A and B. Nine of 10 animals also exhibited ADCC activity against HIV subtype C and CRF01_AE gp120-coated targets. This subtype B Ad-HIV recombinant prime/envelope protein boost regimen is a promising approach for eliciting broad ADCC activity against diverse HIV clades. Incorporating additional non-subtype B envelope genes and protein boosts in a multivalent strategy may be required to elicit broader neutralizing antibodies against non-subtype B HIV strains.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>16940858</pmid><doi>10.1097/01.qai.0000230318.40170.60</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 2006-11, Vol.43 (3), p.270-277 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69024970 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Ovid Autoload; Free E- Journals |
| subjects | Adenoviridae - genetics Adenovirus Adenoviruses AIDS Vaccines - administration & dosage AIDS Vaccines - immunology AIDS/HIV Animals Biological and medical sciences Cross Reactions Drug Evaluation, Preclinical Fundamental and applied biological sciences. Psychology Genetic Vectors - immunology HIV HIV Antibodies - blood HIV Antibodies - immunology HIV Envelope Protein gp120 - immunology HIV Infections - immunology HIV Infections - prevention & control HIV-1 - classification HIV-1 - genetics HIV-1 - immunology Human immunodeficiency virus Human viral diseases Immune system Immunization, Secondary Infectious diseases Medical sciences Microbiology Miscellaneous Neutralization Tests Pan troglodytes Proteins Recombinant Proteins - immunology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Synthetic - immunology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Vaccines - administration & dosage Virology |
| title | An Adenovirus-Based HIV Subtype B Prime/Boost Vaccine Regimen Elicits Antibodies Mediating Broad Antibody-Dependent Cellular Cytotoxicity Against Non-Subtype B HIV Strains |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A50%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20Adenovirus-Based%20HIV%20Subtype%20B%20Prime/Boost%20Vaccine%20Regimen%20Elicits%20Antibodies%20Mediating%20Broad%20Antibody-Dependent%20Cellular%20Cytotoxicity%20Against%20Non-Subtype%20B%20HIV%20Strains&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=G%C3%B3mez-Rom%C3%A1n,%20V.%20Ra%C3%BAl&rft.date=2006-11-01&rft.volume=43&rft.issue=3&rft.spage=270&rft.epage=277&rft.pages=270-277&rft.issn=1525-4135&rft.eissn=1944-7884&rft.coden=JDSRET&rft_id=info:doi/10.1097/01.qai.0000230318.40170.60&rft_dat=%3Cproquest_cross%3E69024970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=233641777&rft_id=info:pmid/16940858&rfr_iscdi=true |